
Figure 1. Effect of Ranolazine on HbA1c Levels





CARISA Primary Endpoint:
Exercise Duration at Trough
DM
No DM
Change from Baseline (sec)*
140
120
100
80
60
40
55
68
60
Placebo
RAN 750 mg bid
RAN 1000 mg bid
= N
* (LS Mean + SE LS Mean)
Treatment-by-Diabetes interaction p = 0.89

Figure 2



CARISA: Exercise Duration at Peak
DM
No DM
Change from Baseline (sec)*
40
60
80
100
120
140
55
67
59
N =
Placebo
RAN 750 mg bid
RAN 1000 mg bid
*(LS Mean + SE LS Mean)
Treatment-by-Diabetes interaction p = 0.58

Figure 3



CARISA: Exercise Time to Onset of Angina
DM
No DM
TROUGH*
PEAK*
Change from 140 Baseline (sec)*
200
180
160
140
120
100
80
60
Placebo
RAN 750 mg bid
RAN 1000 mg bid
* (LS Mean + SE LS Mean)
** Treatment-by-Diabetes interaction p = 0.54 at trough; p = 0.26 at peak

Figure 4



CARISA: Change from Baseline in HbA1c
(All Diabetic Patients)
Baseline
Last Study Value
HbA1c
%age
9
8
7
6
5
*p = 0.008
*p = 0.0002
Placebo
RAN 750 mg
bid
RAN 1000 mg
bid
*Difference vs. Placebo

Figure5



CARISA: Change from Baseline in HbA1c
(Dependent vs Non-Insulin Dependent
Diabetic Patients)
Baseline
Last Study Value
Insulin Dependent
Non-Insulin Dependent
*p = 0.02
*p = 0.09
*p = 0.008
*p = 0.007
HbA1c
(%age)
9
8
7
6
5
Placebo
RAN 750
mg bid
RAN 1000
mg bid
Placebo
RAN 750
mg bid
RAN 1000
mg bid
*Difference vs. Placebo

Figure 6